<?xml version="1.0" encoding="UTF-8"?>
<p>Worldwide, cisgender men who have sex with men (MSM) are disproportionately impacted by HIV infection [
 <xref rid="pone.0221558.ref001" ref-type="bibr">1</xref>, 
 <xref rid="pone.0221558.ref002" ref-type="bibr">2</xref>]. Daily oral use of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as pre-exposure prophylaxis (PrEP) effectively prevents HIV infection [
 <xref rid="pone.0221558.ref003" ref-type="bibr">3</xref>–
 <xref rid="pone.0221558.ref006" ref-type="bibr">6</xref>] and has the potential to curb HIV epidemics among MSM globally [
 <xref rid="pone.0221558.ref007" ref-type="bibr">7</xref>–
 <xref rid="pone.0221558.ref010" ref-type="bibr">10</xref>]. In 2014, the World Health Organization (WHO) released guidelines recommending PrEP for MSM at substantial risk of HIV infection [
 <xref rid="pone.0221558.ref011" ref-type="bibr">11</xref>]. Yet, to-date, PrEP implementation and uptake have been slow and mainly concentrated among MSM in high-income countries [
 <xref rid="pone.0221558.ref012" ref-type="bibr">12</xref>, 
 <xref rid="pone.0221558.ref013" ref-type="bibr">13</xref>].
</p>
